You never formulated a topical medicated product, and you wish to speed up its development. How to start?

How to include early clinical results in the development of your topical dermal product?
RiverD, has a solution. Watch our interview

Introduction of Dr. Maria Lapteva from University of Geneva Meet Dr. Maria Lapteva, senior scientist at Prof. Kalia’s lab in the Pharmaceutical School of the University of Geneva. She will talk about nanoparticles in skin delivery for the hybrid workshop

I’m Stefan Mühlebach, Prof. em. in Pharmacology and Hospital Pharmacy at the University of Basel in Switzerland. Due to my activity in nanopharmaceutical and regulatory science, I was a founding member of the Non-Biological Complex Drugs working party in the Netherland more the 10 years ago.

My name is Richard Guy.  I am Professor of Pharmaceutical Science at the University of Bath in the UK.  Since 2013, my research has been funded by the FDA’s Office of Generic Drugs to develop and validate methods to assess the bioequivalence of topical drug products.

Dr. Vinod Shah, one of the hybrid workshop speakers about the Quality and Equivalence of Topical Products and Nanotechnology Challenges, is introducing his talk. This event will be held on 6 April 2021 in Geneva.

Christian Surber, Ph.D., is Professor of Dermatopharmacology and Hospital Pharmacy at the University of Basel and visiting Professor at the Departments of Dermatology in Basel and Zürich, Switzerland.

Let’s get prepared ! Here are some snapshots  of the preparation of the workshop  (EMA newly coming guideline on Quality and Equivalence of Topical Products and Nanotechnology Challenges-6 April 2021) with some of the speakers and the moderator.

Teledyne Hanson is a global technology company based in Southern California that invents, engineers, and manufactures dissolution and diffusion test instruments that set the standard for the entire industry. We take great pride in the fact that our research and

Prices of dermal application drugs (topical products) exploded in the USA between 2009 and 2015 (rise of between 2 and 10 times!) due to weak competition. Furthermore, faced with exorbitant expenses and inconclusive clinical study results, allowing the launch of